Rigel Pharmaceuticals, Inc.
395 articles with Rigel Pharmaceuticals, Inc.
-
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/2/2021
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel's RIP1 inhibitor program - Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients - Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update
2/23/2021
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results after market close on Tuesday, March 2 , 2021.
-
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
2/18/2021
Eli Lilly and Company (NYSE: LLY) and Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases
-
Eli Lilly is jumping into the RIPK1 chase, paying $125 million up front to partner with Rigel Pharmaceuticals to co-develop its lead RIPK1 inhibitor program across all indications.
-
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
1/29/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients.
-
Rigel Pharmaceuticals Provides Business Update - Jan 11, 2021
1/11/2021
Rigel Pharmaceuticals, Inc. provided a business update, including preliminary total revenue, TAVALISSE® bottles sold for the quarter, Fast Track designation granted for warm autoimmune hemolytic anemia, and the company's expanding COVID-19 program.
-
Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/7/2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 10:00 a.m. Eastern Time . To access the li
-
Many drug makers are investing in new science and hope to develop new therapeutics that address autoimmune disease. BioSpace has captured some key efforts.
-
Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
12/4/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020.
-
Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
11/23/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Medison Pharma (Medison) today announced that Health Canada has approved the new drug submission (NDS) for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to other treatments.
-
Rigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
11/17/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the final design of its FORWARD study, a pivotal Phase 3 clini
-
Rigel to Present at the Jefferies Virtual London Healthcare Conference
11/10/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:00 p.m. Eastern Time . To access the live an
-
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update
11/5/2020
Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2020, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
10/29/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2020 financial results after market close on Thursday, November 5 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to di
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Rigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
10/9/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.
-
Clinical Catch-Up: September 14-18
9/21/2020
It was a fairly busy week for clinical trial announcements, with some important and interesting news about COVID-19 treatments and vaccines, as well as numerous stories about non-COVID-19 studies. -
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
9/17/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (N
-
Rigel to Present at Two Upcoming Investor Conferences
9/9/2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in September. Investor Presentations: H.C. Wainwright 22 nd Annual Global Investment Conference Date: Tuesday
-
Rigel to Participate in Citi's 15th Annual BioPharma Virtual Conference
9/2/2020
Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled to participate in a panel discussion on COVID-19 during Citi's 15 th Annual BioPharma Virtual Conference taking place September 9-10, 2020 . Citi Panel Details: Pa